INTRODUCTION
Pharmacogenetics, the study of variability in treatment response because of an individual's genetic constitution, traces its origins to the mid-20th century [1, 2] . Pharmacogenomics, often used interchangeably with pharmacogenetics, focuses on how a drug influences gene expression across the entire genome [1, 3] . Whereas pharmacogenomic investigation provides valuable mechanistic insight and facilitates the development of novel therapies, pharmacogenetic investigation identifies individuals predisposed to benefit or harm from a particular therapy and, therefore, serves as a lynchpin of personalized medicine.
Pharmacogenetic investigation requires one or more genetic biomarkers with which to stratify a population to test for differential drug effect. Single nucleotide polymorphisms (SNPs) serve as the most commonly utilized pharmacogenetic biomarkers, but larger structural variants, including insertions, deletions, copy number variations and inversions have also been explored [4] [5] [6] . The frequency of gene variants can vary substantially across genetic ancestral groups, and needs to be taken into account during the study design phase of pharmacogenetic investigation. Pharmacogenetic biomarkers are chosen because of a plausible influence on a drug's pharmacokinetics -distribution, elimination, absorption, and metabolism -or pharmacodynamics -modulation of a disease-causing or disease-palliating molecular pathway [3] .
Within pulmonary medicine, pharmacogenetic investigation has shed light on important drug-gene interactions among individuals with asthma [7] [8] [9] [10] and chronic obstructive pulmonary disease [11] [12] [13] . Less is known about the role pharmacogenetics plays among patients with interstitial lung disease (ILD). This paucity of data stems from multiple factors. First and foremost is the phenotypic heterogeneity of the disease processes that comprise ILD. Despite shared clinical, radiographic, and pathologic features, the natural history of individual ILDs, along with their response to therapy, varies widely [14] [15] [16] [17] [18] [19] . Also contributing is the low overall disease incidence of ILD, estimated to be 30/100 000 in the United States. [20] Together these factors have restricted therapeutics research to only the most common ILDs, including idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated ILD (CTD-ILD).
Despite these challenges, opportunities abound for pharmacogenetic discovery in patients with ILD. Easily acquired blood samples along with paired clinical data from patient registries and clinical trial datasets provide the components necessary to explore clinically relevant drug-gene interaction in this patient population. In this review, we highlight drug-specific polymorphisms known to influence pharmacokinetics or dynamics and provide an overview of polymorphisms associated with specific ILDs that may influence therapeutic response. We then review past pharmacogenetic testing performed in patients with IPF and highlight a recently identified drug-gene interaction in this population.
DRUG-SPECIFIC PHARMACOGENETIC BIOMARKERS
ILD etiology guides therapeutic selection in this patient population. ILDs characterized predominantly by inflammation, including most CTD-ILDs, are often treated with immunomodulatory compounds, such as corticosteroids, azathioprine, mycophenolate mofetil, and tacrolimus. The antifibrotic agents pirfenidone and nintedanib were recently approved for the treatment of IPF, which represents a fibrotic-predominant process. These therapies also hold promise for patients with systemic sclerosis, a connective tissue disease (CTD) in which fibrosis predominates, and are under investigation.
Although the aforementioned therapies have unique mechanisms of action, all undergo extensive hepatic processing and may, therefore, be influenced by polymorphisms within genes involved in this process. Of particular importance are variants within genes encoding hepatic cytochrome p450 protein superfamily, uridine 5'-triphosphate glucuronosyltransferases, N-acetyltransferases, and sulfonyltransferases [21] . Because the role each of these enzymes plays in drug metabolism has been extensively characterized, their genetic structure and functional polymorphisms are well documented. Drug-specific polymorphisms with potential pharmacogenetic relevance are outlined below.
Corticosteroids
After the binding of corticosteroid to the glucocorticoid receptor, this complex is transported into the nucleus of the cell where it inhibits transcription of proinflammatory genes and induces transcription of anti-inflammatory genes [22] . Corticosteroids are commonly used as an adjunct to other immunomodulatory therapies in patients with CTD-ILD [23] . Polymorphisms within NR3C1, which encodes the glucocorticoid receptor, have been associated with increased glucocorticoid sensitivity in healthy adults and corticosteroid dependency in children with inflammatory bowel disease [24, 25] . Additionally, polymorphisms within CRHR1, encoding the corticotrophin-releasing hormone receptor, STIP1, encoding an adaptor protein within the intracellular glucocorticoid receptor heterocomplex and TBX21, encoding a transcription factor that influences T-lymphocyte production, have been associated with differential inhaled corticosteroid responsiveness in patients with asthma [26] [27] [28] .
Azathioprine
A prodrug of mercaptopurine, azathioprine inhibits B and T lymphocyte production through disruption of DNA synthesis. Azathioprine is commonly used to treat a wide variety of autoimmune conditions, including ILD associated with rheumatoid arthritis (RA) [29] , Sjogren's disease [30] , systemic sclerosis [18, 31, 32] and myositis [33] [34] [35] . To become the metabolically active mercaptopurine, azathioprine requires activation by the enzyme thiopurine methyl-transferase (TPMT). Polymorphisms within TPMT, the gene encoding the TPMT enzyme, have been shown to modulate drug bioavailability and adverse event risk, including bone marrow toxicity and gastrointestinal intolerance [36, 37] . Such findings have led to consensus statements across multiple specialties that offer practice guidelines
KEY POINTS
Pharmacogenetic investigation has the potential to guide therapeutic selection in patients with ILD.
Polymorphisms within genes critical to drug processing or disease activity represent relevant genetic biomarkers with which to conduct pharmacogenetic investigation N-acetylcysteine may be an effective therapy for genetically predisposed individuals with IPF.
based on TPMT genotype testing [38] [39] [40] [41] . Genes encoding other enzymes critical to azathioprine processing, including aldehyde oxidase and xanthine oxidase, also offer potential for pharmacogenetic investigation in ILD, as polymorphisms within these genes have been linked to differential azathioprine response among individuals with inflammatory bowel disease [42] .
Mycophenolate mofetil
Like azathioprine, mycophenolate mofetil is commonly used to treat CTD-ILD and has been shown to preserve lung function in this population [43] [44] [45] . Mycophenolate mofetil is rapidly converted to mycophenolic acid (MPA), which then blocks B and T-lymphocyte proliferation through selective inhibition of inosine monophosphate dehydrogenase. Polymorphisms within inosine monophosphate dehydrogenase have been shown to markedly reduce the in-vitro antiproliferative effects of MPA [46] and have the potential to influence drug response. MPA is subsequently inactivated by hepatic UDP-glucuronosyltransferase (UGT). Polymorphisms within UGT1A9 have been associated with a significant increase in UDP-glucuronosyltransferase activity, thereby reducing the amount of circulating bioactive MPA [47] . Although these polymorphisms still have unclear clinical consequences, further investigation is warranted.
Tacrolimus
A calcineurin inhibitor used most often to prevent solid organ transplant rejection, tacrolimus has also been shown to slow pulmonary function decline and improve outcomes in patients with myositisassociated ILD [48] [49] [50] . Polymorphisms within cytochrome p450 genes CYP3A5 and CYP3A5 have been shown to influence the bioavailability of tacrolimus [51] . Absorption of tacrolimus may also be influenced by the presence of polymorphisms within the MDR1 gene, which encodes a cellular efflux pump protein [52] .
Pirfenidone and nintedanib
These antifibrotic agents were recently approved in the United States for the treatment of patients with IPF after phase 3 clinical trials demonstrated efficacy in the slowing of pulmonary function decline [53] [54] [55] . Athough its exact mechanism of action remains incompletely characterized, pirfenidone has been shown to reduce human fibroblast proliferation and myofibroblast differentiation through attenuation of transforming growth factor-b expression (TGF-b) and downstream signaling pathways [56, 57] . Polymorphisms within TGF-b have been linked to an increased risk of pulmonary fibrosis in patients with sarcoidosis and liver fibrosis in those with hepatitis C and alcoholic abuse [58, 59] , raising the question of whether pirfenidone may differentially affect patients with IPF carrying these polymorphisms.
Nintedanib attenuates myofibroblast proliferation through inhibition of receptors for fibroblast growth factor (FGFR) and platelet-derived growth factor [60] . Polymorphisms within several fibroblast growth factors and platelet-derived growth factor have been linked to various types of cancer, including colon [61] , breast [62] and thyroid [63] . Whether the presence of such polymorphisms in patients with IPF would affect nintedanib efficacy remains unknown. A complete list of drug-specific biomarkers with potential pharmacogenetic relevance is shown in Table 1 .
DISEASE-SPECIFIC PHARMACOGENETIC BIOMARKERS
The emergence and rapid expansion of highthroughput genomic technology has led to the identification of many novel genetic loci associated with specific disease states. Based on the assumption that genes at these loci contribute to disease onset and/or activity, polymorphisms within these genes have the potential to influence the pharmacodynamics of therapies used to treat the disease [64] .
Idiopathic pulmonary fibrosis
Within ILD, IPF remains the best characterized to date. Among individuals with familial interstitial pneumonia (FIP), the heritable form of IPF, rare mutations within genes involved in surfactant production, [65] [66] [67] [68] [69] and telomere stability [70, 71] were the first gene variants to be identified in IPF. More recently, two groups identified rare mutations in RTEL1, which encodes an important regulator of telomere elongation, to be associated with FIP susceptibility using whole-exome sequencing [ ]. The rare nature of these mutations will likely limit their utility in pharmacogenetic modeling, but similar effects along shared pathways may allow for aggregation of certain mutations to generate larger cohorts.
Among patients with sporadic IPF, numerous genetic and genomic investigations have identified common gene variants associated IPF susceptibility ( ,83-85]. The short arm of chromosome 11 has received considerable attention, as two genes strongly associated with IPF susceptibility, TOLLIP and MUC5B, reside at this locus [74] [75] [76] . TOLLIP encodes Toll-interacting protein, which acts to inhibit Toll-like receptor (TLR) signaling. Several TLRs are active in the lung, including TLR2 and TLR4, and have been shown to be vital mediators of the innate and adaptive immune response [86] [87] [88] [89] [90] . MUC5B encodes a highly glycosylated protein that contributes to airway mucus production and also functions to maintain immune homeostasis [87, 91, 92] . In addition to their association with IPF susceptibility, two SNPs -rs5743890 within TOLLIP and rs35 705 950 within MUC5B -are associated with differential survival [74, 93] .
Additional loci linked to IPF by genome-wide association study (GWAS) and other genetic investigations, include MDGA2 [74] , SPPL2C [74] , MAPT [76] , LRRC34 [76] , FAM13A [76] , DSP [76] , OBFC1 [76] , MUC2 [76] , ATP11A [76] , DPP9 [76] , TERT [76, 77] , IL-8 [78] , IL1RN [79, 80] , TNF-a [80] , HLA-DRB1 [81] , HSP70 [82 & ], and CDKN1A [83] . Although identification of these variants has advanced our understanding of how IPF develops, few have been shown to predict survival. The highly variable natural history of IPF, whereby some patients remain stable over many years, others progress steadily and some die from rapidly progressive disease, suggests that some genes may contribute to disease onset whereas others contribute to disease progression [94] [95] [96] . Indeed, several polymorphisms associated with disease activity, but not susceptibility, have been identified within TP53 [83], TLR3 [84] , and TGFB1 [85] .
Connective tissue disease-associated interstitial lung disease
Although several GWAS have been conducted in patients with CTD, none have been performed in specifically in patients with CTD-associated ILD. But because immune-mediated mechanisms are believed to be responsible for ILD development in these patients, polymorphisms associated with specific disease states may serve as relevant pharmacogenetic biomarkers (Table 3 ). Among the bestcharacterized CTDs is RA. In 2010, investigators conducted a GWAS meta-analysis in over 12 000 RA cases that confirmed known susceptibility loci at PTPN22, CTLA4, TNFAIP3, and CD40. This study also identified SNPs within IL6ST, SPRED2, RBPJ, CCR6, IRF5, and PXK to be novel risk loci and SNPs within IL2RA, CCL21, and AFF3 to be novel risk alleles within known risk loci [97] . GWAS in other CTDs have also demonstrated a strong association between disease susceptibility and polymorphisms within genes involved in immune signaling. A GWAS conducted in over 2 000 patients with systemic sclerosis identified several risk loci within the major histocompatibility complex (MHC) on chromosome 6 and at CD247, IRF5, and STAT4 [98] . MHC SNPs have also been strongly associated with disease susceptibility in patients with poly and dermatomyositis, as have risk loci at PLCL1, BLK, and CCL21 [99, 100] . Substantial overlap in risk loci exists between the aforementioned CTDs and patients with Sjogren's syndrome, which can result in several types of lung disorders, including ILD. In a GWAS of patients with Sjogren's syndrome, risk loci were again identified within MHC genes, along with IRF5, BLK, and STAT5. A novel risk locus was also was identified at IL12A [101] . Because the overwhelming majority of SNPs associated with CTD lie within genes critical to immune signaling, such polymorphisms have a high potential to influence the response to immunomodulatory therapy. MAF, minor allele frequency. a Based on population of reference cited. Actual MAF will vary depending on ancestral background of study population.
DRUG-GENE INTERACTION IN PATIENTS WITH IPF
The first suggestion of drug-gene interaction in patients with IPF was reported as secondary analyses of a GWAS [74] and survival analysis [93] . DNA samples from patients enrolled in the 'Anti-Coagulant Effectiveness in Idiopathic Pulmonary Fibrosis' trial [102] were among those used to conduct our group's recent GWAS. Post hoc analysis of this cohort (reported in the supplement) showed possible interaction between warfarin therapy and the MUC5B promoter polymorphism, though the small sample size precluded formal interaction testing. It was observed that among genotyped trial participants, more deaths occurred in those with the polymorphism who received warfarin compared with placebo (6 warfarin vs. 1 placebo), suggesting a possible interaction.
In their survival analysis of the MUC5B promoter polymorphism [93] , Peljto and colleagues used DNA samples collected from patients enrolled in 'The INSPIRE Trial: A Study of Interferon g-1b for Idiopathic Pulmonary Fibrosis 0 [103] . These authors showed that the survival benefit associated with this polymorphism was stronger among those receiving interferon g-1b compared with placebo. Although formal interaction analysis failed to cross the significance threshold (p interaction ¼ 0.07), it did raise the question of whether this therapy may have been more efficacious in those carrying the polymorphism. The authors did point out however that the survival benefit observed with the polymorphism in the INSPIRE cohort would not be expected in the University of Chicago replication cohort if this benefit was due solely to drug-gene interaction. In December 2015, our group published the first dedicated pharmacogenetic investigation conducted in patients with IPF to date [104 && ]. This was performed using paired genetic and clinical data from patients enrolled in the 'Effectiveness of Prednisone, Azathioprine, and N-Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis' (PAN-THER) clinical trial [19, 105] . Common SNPs within TOLLIP and MUC5B were genotyped and tested for interaction with trial interventions, including N-acetylcysteine (NAC) monotherapy and combination therapy with prednisone, azathioprine, and NAC, using a composite end point of death, transplantation, hospitalization and !at least 10% decline in forced vital capacity.
Using a multivariable Cox proportional hazards model, we identified significant interaction between NAC monotherapy and rs3 750 920, a coding SNP within exon 3 of TOLLIP. Genotype-stratified Kaplan-Meier curves and Cox models were constructed ( Fig. 1 ) and showed that those with a CC genotype had an increased composite end point risk whereas those with a TT genotype had a decreased risk. Sensitivity analysis showed that the increased risk among those with a CC genotype was driven primarily by forced vital capacity decline events, whereas the decreased risk associated with the TT genotype was consistent across all end points. These findings were then replicated in an independent IPF cohort of patients followed at the University of Chicago and enrolled in the INSPIRE clinical trial. This study had several limitations, including its post hoc, exploratory design and small sample size (<50% of PANTHER participants consented to genetic analysis). Despite these limitations, this study again raised the question of whether NAC may be an efficacious therapy for some patients with IPF and supports the pursuit a genotype-stratified NAC clinical trial. Furthermore, it highlighted the importance of pharmacogenetic investigation in patients with IPF, and ILD in general, and underscored the need for biospecimen collection in this patient population.
CONCLUSION
As medicine strives to usher in an era of personalized medicine, extensive pharmacogenetic investigation will be necessary to make this goal a reality. Prospective, randomized, genotyped-stratified clinical trials have already been conducted in patients with asthma [106, 107] , and provide a template for implementation in ILD. Prior to formal testing in clinical trials, drug-gene interaction must first be identified using paired DNA and clinical data from patient registries and completed clinical trials. Patient and provider education will be paramount in this endeavor, as biospecimens will be needed for such work and should be collected from as many patients as possible. Equally important will be a coordinated effort among ILD centers, not only to ensure robust pharmacogenetic testing, but to also expand clinical trial access to patients with less common ILDs.
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